 |
|
04-21-2011, 11:30 PM
|
#41
|
|
Senior Member
Join Date: Feb 2006
Location: Southern, CA
Posts: 2,511
|
Re: Started Intrathecal Herceptin Today
Courtney,
That is fantastic news! Such a wonderful word "negative" can be.  I'm so glad you got such great news. I hope the intrathecal Herceptin injections kick butt on those buggers. I will continue to keep you in my thoughts and prayers. Now you guys can relax a little and enjoy your Easter. Thanks for the update...I was wondering how you were doing. Enjoy!
Chelee
__________________
DX: 12-20-05 - Stage IIIA, Her2/Neu, 3+++,Er & Pr weakly positive, 5 of 16 pos nodes.
Rt. MRM on 1-3-06 -- No Rads due to compromised lungs.
Chemo started 2-7-06 -- TCH - - Finished 6-12-06
Finished yr of wkly herceptin 3-19-07
3-15-07 Lt side prophylactic simple mastectomy. -- Ooph 4-05-07
9-21-09 PET/CT "Recurrence" to Rt. axllia, Rt. femur, ilium. Possible Sacrum & liver? Now stage IV.
9-28-09 Loading dose of Herceptin & started Zometa
9-29-09 Power Port Placement
10-24-09 Mass 6.4 x 4.7 cm on Rt. femur head.
11-19-09 RT. Femur surgery - Rod placed
12-7-09 Navelbine added to Herceptin/Zometa.
3-23-10 Ten days of rads to RT femur. Completed.
4-05-10 Quit Navelbine--Herceptin/Zometa alone.
5-4-10 Appt. with Dr. Slamon to see what is next? Waiting on FISH results from femur biopsy.
Results to FISH was unsuccessful--this happens less then 2% of the time.
7-7-10 Recurrence to RT axilla again. Back to UCLA for options.
|
|
|
|
04-21-2011, 11:51 PM
|
#42
|
|
Senior Member
Join Date: Oct 2008
Posts: 88
|
Re: Started Intrathecal Herceptin Today
Congratulations Courtney!
Wow - that was quick. You must be sooooo relieved.
;-) - Kim
__________________
------------------------------
Dx Stage 3C 2005, triple +, tons of lymph nodes as well. FEC, surgery, TCH, rads, herceptin 1 year. And, Aromasin.
2007 - recurrence to medistinal lymph node, Abraxene and Herceptin - took it down 50%
2008 - on Arimidex/Herceptin - stable lymph node.
2009 - stable on Arimidex/Herceptin
2010 - lymph node progression and liver mets.
2010 - went on Gemzar, Navelbine, Herceptin - Navelbine and Herceptin took liver mets down. lymph node slightly progressed.
2010 - did Xeloda & Tykerb - MAJOR progression in liver in only 6 weeks.
Dec 2010 - present - Ixempra/Avastin/Herceptin/Fasoldex - regressing
June 2012 - chemo break
Sept 19, 2012 - start t-dm1. Chose this over going back on Ixempra.
|
|
|
|
|
04-22-2011, 09:10 AM
|
#43
|
|
Senior Member
Join Date: Feb 2008
Location: Georgia
Posts: 1,486
|
Re: Started Intrathecal Herceptin Today
Courtney,
So glad to hear from you. You have made my day.
Amelia
|
|
|
|
|
04-23-2011, 08:11 PM
|
#44
|
|
Senior Member
Join Date: Oct 2009
Posts: 84
|
Re: Started Intrathecal Herceptin Today
Courtney! I've been looking for you and am so glad to have found you again! I tried to find you on Caringbridge to no avail. Please send me that info if you can. My daughter just had her first SRS treatment on 5 of her brain mets and goes back for them to do the other next week. Can you tell me more about the INtrathecal Herceptin? You can email me at Jjeldance@aol.com! My best to you always
Joyce |
|
|
|
|
04-30-2011, 02:38 PM
|
#45
|
|
Senior Member
Join Date: Jan 2010
Location: Matakana which is one hour north of Auckland, New Zealand.
Posts: 89
|
Re: Started Intrathecal Herceptin Today
Hi Courtney
Wow sounds like you had a great trip down to NZ. You picked the right time of year. The weather has got cold and wet, winter is on its way. Did you manage to get up to the north island?
I've only just been reading these post on Intracthecal Herceptin how is it going?
I'm still recovering from WBR and VMAT all went well and other than losing may hair again I feel good just waiting for my next scan result in four weeks to see how successful it was. For my my next option is to travel overseas for gamma.
I'm going to onc 18 May and going to see if this intrathecal herceptin is an option for me to.
Thank you for being so brave you really are leading the way for others and certainly give confidence for me to try new and improved technology. Hope you feel good, take care.
Regards
Jacqui
__________________
Oct 2009 Masectomy 6 cm Tumor . Sentinal node biopsy , Node Positive . Her2 + er/pr -.
Nov 2009 X3 Taxane and Herceptin, X3 FEC
March 2010 25 Rads
March 2010 continued on Herception untill 16 Dec 2010
May 2010 Ultra Sound .... ALL CLEAR... NED
August 2010 started vaccine trial University of Washington
7th Dec 2010 finished vaccine trial
20th Dec 2010 Port removed
3rd Feb no longer ned brain mets
23r Feb start VMAT radiation
August 2011 two new mets to brain and others starting to grow again !!!!
August start tykerb and xeloda
Dec 1 MRI all small brain mets gone. Largest shrunk by 50% only three small ones to go 17mm,8mm,6mm. Mets on there way out. Yeah
|
|
|
|
|
05-03-2011, 07:11 PM
|
#46
|
|
Senior Member
Join Date: Jul 2008
Location: New Boston, NH
Posts: 275
|
Re: Started Intrathecal Herceptin Today
What fantastic news! I am so happy for you! I will continue to pray that the intrathecal herceptin works. I feel like it is the key!
__________________
-Sarah-
Jan '07 felt lump (PCP "thought" it was a cyst)
Nov '07 "bloody nipple discharge" (OB-GYN "thought" I had fibrocystic breasts and told me to take 400 IU's of Vitamin E)
Note: Mother was dx w/BC in 2004 (ER/PR+ & HER2+) & mets to brain April 2007 (she passed away June 17, 2008)
2/1/08: Biopsy Dx: DCIS (age 34)
2/22/08: Surgery R-side Mast
2/28/08: 1st Path Rpt Dx: IDC 1.8cm tumor & DCIS 2.1cm
2nd Path Rep DFCI - IDC (0.9cm) & DCIS (2.1cm)
Stage 1b/Gr 3; ER+(5%), PR+(2%), HER-2+++
5/5 nodes NEG; Clear Margins
Chemo: AC 4 rnds (1st one 3/31/08) finished 6/2/08
TH (Taxol/Hercepin) 12 weeks (1st one 6/25/08) finished 9/8/08
Herceptin 9 mos (every 3 weeks) finished 6/8/09
BRCA 1/2 NEG
Bio: Age 39, married to James 1999, 2 boys 12 & 10 yo
|
|
|
|
|
05-05-2011, 03:53 PM
|
#47
|
|
Senior Member
Join Date: Mar 2006
Posts: 4,778
|
Re: Started Intrathecal Herceptin Today
hot off the press:
just shows your are a pioneer pushing the limits of the latest and greatest
Bull Cancer. 2011 May 4. [Epub ahead of print]
Leptomeningeal meningitis related to breast cancer overexpressing HER2: is there a place for a more specific treatment?
Gutierrez M, Lyazidi S, Brasseur L, Cvitkovic F, Le Scodan R.
Abstract
Leptomeningeal metastases are very commonly associated with breast cancer. The prognosis is very poor in the short term with an overall median survival less than 6 months. Based on pragmatic and historical considerations intrathecal chemotherapy (IT) are considered to be the adequate treatment. However overall results are disappointing. Despite specific and symptomatic treatment, improvement in survival and quality of life remains very modest, highlighting the importance for ongoing research for developing new molecules or on improving the use a better use of those available today. The incidence of leptomeningeal metastases is particularly marked in cases of overexpression of HER2. The main hypothesis is there may be a better control of extra-cerebral localisations with trastuzumab therefore intra-cerebral recurrences may be encountered preferentially as they are not reached by this high molecular weight monoclonal antibody (148 kD). Analyses performed in the cerebrospinal fluid following intravenous trastuzumab showed extremely low levels of the antibody and support the hypothesis that leptomeningeal metastasis of HER2-overexpressing breast carcinoma remain potentially sensitive to HER2-type receptor inhibition by a target agent under the condition of by-passing the meningeal blood brain barrier. Intra-ventricular or IT administered with trastuzumab would reach high loco-regional therapeutic concentrations in the cerebro-meningeal without risk for normal non-expressing HER2 leptomeningeal tissue. This strategy has been successfully tested on several animal models. A limited number of administrations in humans have been described in the literature, with weekly doses up to 100 mg. No specific toxicity has been described and some data suggest a potential benefit in survival despite the real difficulties for adequate interpretations. Furthermore, a multicentric phase I-II clinical trial, of which the Curie institute is the sponsor and investigating the intra-thecal administration and the efficacy of the trastuzumab will begin very soon. More studies are needed to measure the exact impact of small molecule inhibitors of tyrosine kinase on the leptomeningeal localizations.
PMID: 21540147 [PubMed - as supplied by publisher]
|
|
|
|
Posting Rules
|
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts
HTML code is Off
|
|
|
All times are GMT -7. The time now is 01:33 PM.
|
Linear Mode
